Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (AU:ZLD)
ASX:ZLD
RESEARCH TOOLSreports
Holding AU:ZLD?
Track your performance easily
ZLD Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.28 - AU$1.95
Previous CloseAU$0.76
Volume1.78K
Average Volume (3M)8.46K
Market Cap
AU$17.67M
Enterprise ValueAU$6.81M
Total Cash (Recent Filing)AU$2.75M
Total Debt (Recent Filing)AU$500.91K
Price to Earnings (P/E)―
Beta-0.67
Next Earnings
Aug 29, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.22
Shares Outstanding9,577,116
10 Day Avg. Volume4,248
30 Day Avg. Volume8,457
Standard Deviation0.77
R-Squared0.03
Alpha0.12
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)33.90
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Zelira Therapeutics News
PremiumCompany Announcements
Zelira Therapeutics Gains Momentum with FDA
PremiumCompany Announcements
Zelira Therapeutics Boosts Capital with Chairman’s Loan
PremiumCompany Announcements
Zelira Therapeutics Advances with New Funding
PremiumCompany Announcements
Zelira Therapeutics Balances Cash Flow
PremiumCompany Announcements
Zelira Therapeutics Advances Key Cannabis ProgramsPremiumCompany Announcements
Zelira Therapeutics Secures R&D Tax Incentive BoostZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.28 and its highest was AU$1.95 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Currently, no data Available
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Aug 29, 2024 which is 116 days ago.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Feb 22, 2024. The company reported -AU$3.008 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$3.008.
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,347,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -AU$3.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.149%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
---
Zelira Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:ZLD Sentiment 75%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.10%
12-Months-Change
Fundamentals
Return on Equity
-235.77%
Trailing 12-Months
Asset Growth
-90.72%
Trailing 12-Months
Company Description
Zelira Therapeutics
Zelira Therapeutics Ltd, formerly Zelda Therapeutics Ltd is an Australia-based biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in a breast, brain, and pancreatic cancer.
---
Technical Analysis
Zelira Therapeutics
―
Corbus Pharmaceuticals
―
Cara Therapeutics
―
Curaleaf Holdings
―
Gryphon Digital Mining
―
---